News

New drug pricing scheme could politicise decisions and reduce access, says think tank

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f2965 (Published 08 May 2013) Cite this as: BMJ 2013;346:f2965
  1. Adrian O’Dowd
  1. 1London

The new proposed drug pricing scheme for the United Kingdom known as value based pricing could turn patients into “political pawns” and make it harder for them to get some drugs, an independent healthcare think tank has said.

The think tank, 2020health, published a report on 7 May in which it raises several concerns about the government’s plan to change the way that drugs are priced from next year.1 The report examines the implications of the new arrangements for patients.

Under the current system for pricing drugs, known as the Pharmaceutical Price Regulation Scheme (PPRS), the price of individual drugs is not controlled, but companies’ total revenue from the NHS is limited.

The new system of value based pricing, which is due to be …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe